Patents by Inventor Lori Hazlehurst
Lori Hazlehurst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210347826Abstract: Embodiments of the present disclosure generally relate to cyclic peptidomimetic compounds and methods for making the same. Other embodiments relate to a method of treating a disease by administering a pharmaceutically effective amount of a cyclic peptidomimetic disclosed herein, for example to treat cancer.Type: ApplicationFiled: June 5, 2019Publication date: November 11, 2021Inventors: Mark MCLAUGHLIN, Lori HAZLEHURST
-
Patent number: 11078235Abstract: The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant cells).Type: GrantFiled: July 2, 2018Date of Patent: August 3, 2021Assignees: H. Lee Moffitt Cancer Center And Research Institute, Inc., The Scripps Research Institute, University of South FloridaInventors: Lori Hazlehurst, Christoph Rader, Xiuling Li, Mark McLaughlin
-
Publication number: 20190092812Abstract: The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant cells).Type: ApplicationFiled: July 2, 2018Publication date: March 28, 2019Inventors: Lori Hazlehurst, Christoph Rader, Xiuling Li, Mark McLaughlin
-
Publication number: 20180362583Abstract: Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.Type: ApplicationFiled: August 27, 2018Publication date: December 20, 2018Inventors: Lori Hazlehurst, Mark McLaughlin, Priyesh Jain, William S. Dalton
-
Patent number: 10059740Abstract: Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.Type: GrantFiled: May 26, 2016Date of Patent: August 28, 2018Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF SOUTH FLORIDAInventors: Lori Hazlehurst, Mark McLaughlin, Priyesh Jain, William S. Dalton
-
Patent number: 10011635Abstract: The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant cells).Type: GrantFiled: September 26, 2014Date of Patent: July 3, 2018Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF SOUTH FLORIDA, MODULATION THERAPEUTICS, THE SCRIPPS RESEARCH INSTITUTEInventors: Lori Hazlehurst, Christoph Rader, Xiuling Li, Mark McLaughlin
-
Publication number: 20160257712Abstract: Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.Type: ApplicationFiled: May 26, 2016Publication date: September 8, 2016Inventors: LORI HAZLEHURST, MARK MCLAUGHLIN, PRIYESH JAIN, WILLIAM S. DALTON
-
Publication number: 20160229892Abstract: The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant cells).Type: ApplicationFiled: September 26, 2014Publication date: August 11, 2016Inventors: LORI HAZLEHURST, CHRISTOPH RADER, XIULING LI, MARK MCLAUGHLIN
-
Publication number: 20150071918Abstract: The invention relates to novel cyclic compounds (cyclic peptides), linkers useful as beta-turn promoters in cyclic peptides, and methods for treatment of malignant cells in vitro or in vivo using one or more linear and cyclic peptides. The peptides can act as integrin interaction inhibitors and may be used in the treatment of cancers as monotherapies or in combination with other anti-cancer agents, such as proteasome inhibitors, inhibitors of autophagy, alkylating agents, MEK inhibitors, FAK/PYK2 inhibitors, and EGFR inhibitors. The invention further concerns a method of predicting the binding of a cyclic or linear HYD1 peptide to a cancer cell by assessing overexpression of biomarkers such as CD44, VLA-4 integrin, basigin, CD138 (syndecan 1), NCAM, ICAM1, ICAM3, and CD59.Type: ApplicationFiled: May 9, 2013Publication date: March 12, 2015Inventors: Mark McLaughlin, Lori Hazlehurst, Priyesh Jain, Michael F. Emmons, Anthony W. Gebhard, Rajesh R. Nair
-
Publication number: 20150017259Abstract: Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.Type: ApplicationFiled: August 21, 2014Publication date: January 15, 2015Inventors: LORI HAZLEHURST, MARK MCLAUGHLIN, PRIYESH JAIN, WILLIAM S. DALTON
-
Publication number: 20140322227Abstract: The present invention concerns the use of HYD1 peptides to reduce activated T-cell numbers and/or to promote bone preservation in vivo. The present invention concerns methods of treating a bone deficiency and/or an autoimmune disorder, comprising administering an effective amount of a HYD1 peptide. Another aspect of the invention concerns a pharmaceutical composition comprising a HYD1 peptide and another agent for treating a bone deficiency and/or another agent for treating an autoimmune disorder.Type: ApplicationFiled: April 28, 2014Publication date: October 30, 2014Inventors: LORI HAZLEHURST, MARK MCLAUGHLIN, RAJESH R. NAIR
-
Patent number: 8853149Abstract: Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.Type: GrantFiled: March 21, 2011Date of Patent: October 7, 2014Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., University of South FloridaInventors: Lori Hazlehurst, Mark McLaughlin, Priyesh Jain, William S. Dalton
-
Publication number: 20130065837Abstract: Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.Type: ApplicationFiled: March 21, 2011Publication date: March 14, 2013Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: Lori Hazlehurst, Mark Mclaughlin, Priyesh Jain, William S. Dalton
-
Patent number: 8227434Abstract: The subject invention pertains to materials and methods for treating oncological disorders. The subject invention also pertains to materials and methods for preventing or reducing the development by cancer cells of resistance to an anticancer therapy, such as chemotherapy, radiotherapy and/or immunotherapy. In one embodiment, a patient is treated with an agent that inhibits cholesterol synthesis or that prevents or reduces the increase in cholesterol synthesis observed in therapy-resistant cancer cells. In another embodiment, a patient is treated with an agent that increases the expression, activity, or amount of a Bim protein in a cell. In another embodiment, a patient is treated with an agent to inhibit or reduce cancer cell adhesion to extracellular matrices or stromal cells. In another embodiment, a patient is treated with an agent to inhibit expression of a gene of function of a protein of the FANC/BRCA pathway.Type: GrantFiled: November 4, 2004Date of Patent: July 24, 2012Assignees: H. Lee Moffitt Cancer Center & Research Institute, Inc., University of South FloridaInventors: William S. Dalton, Lori Hazlehurst, Qing Chen
-
Publication number: 20080108552Abstract: The present invention concerns fragments and variants of the HYD1 peptide; polynucleotides encoding the peptides; host cells genetically modified with the polynucleotides; vectors comprising the polynucleotides; compositions containing these peptides, polynucleotides, vectors, or host cells; and methods of using the peptides, polynucleotides, vectors, and host cells as inhibitors of aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as myeloma. The present invention further includes a method of increasing the efficacy of chemotherapy and radiation therapy, comprising administering an agent that binds ?1 integrin to a patient in need thereof. In one embodiment, the ?1 integrin binding agent is the HYD1 peptide, or a functional fragment or variant thereof.Type: ApplicationFiled: September 7, 2007Publication date: May 8, 2008Applicants: University of South Florida, The Regents of the University of California, H. Lee Moffitt Cancer Center & Research Institute, The Arizona Board of Regents on behalf of The University of ArizonaInventors: Lori Hazlehurst, William Dalton, Anne Cress, Kit Lam